The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Τίτλος | The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. |
Publication Type | Journal Article |
Year of Publication | 2007 |
Authors | Poulaki, V., Mitsiades C. S., Kotoula V., Negri J., McMillin D., Miller J. W., & Mitsiades N. |
Journal | Invest Ophthalmol Vis Sci |
Volume | 48 |
Issue | 10 |
Pagination | 4706-19 |
Date Published | 2007 Oct |
ISSN | 0146-0404 |
Λέξεις κλειδιά | Antineoplastic Agents, Apoptosis, Biomarkers, Tumor, Boronic Acids, Bortezomib, Caspases, Cell Proliferation, Flow Cytometry, Formazans, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Immunoblotting, Indicators and Reagents, Neoplasm Proteins, Oligonucleotide Array Sequence Analysis, Protease Inhibitors, Pyrazines, Retinal Neoplasms, Retinoblastoma, Reverse Transcriptase Polymerase Chain Reaction, Tetrazolium Salts, Tumor Cells, Cultured, Up-Regulation |
Abstract | PURPOSE: To evaluate the potential of proteasome inhibitors, a novel class of antitumor agents, for the treatment of retinoblastoma. The proteasome inhibitor bortezomib (PS-341, Velcade; Millennium Pharmaceuticals, Cambridge, MA), approved by the US Food and Drug Administration for the treatment of multiple myeloma, is being studied for the treatment of several other malignancies. Among other effects, it inactivates the transcription factor nuclear factor-kappaB (NF-kappaB) by blocking the degradation of its inhibitor, IkappaB. NF-kappaB, which is constitutively active in human retinoblastoma cells and promotes their survival, represents a therapeutic target for patients with this malignancy. |
DOI | 10.1167/iovs.06-1147 |
Alternate Journal | Invest Ophthalmol Vis Sci |
PubMed ID | 17898295 |